Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
13 août 2020 16h01 HE
|
Acer Therapeutics Inc.
Advanced expanded pipeline of clinical stage product candidates, including emetine for COVID-19 and ACER-001 for Urea Cycle Disorders NEWTON, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Acer...
Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study
08 juil. 2020 16h01 HE
|
Acer Therapeutics Inc.
Model suggests ACER-001, Acer’s taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease management in patients with Urea Cycle Disorders compared to current...
Acer Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
14 mai 2020 16h01 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious...
Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health
11 mai 2020 16h05 HE
|
Acer Therapeutics Inc.
Targeting Q3 2020 initiation of an adaptive Phase 2/3 trial evaluating emetine in high-risk COVID-19 outpatients, following IND submission and clearance Acer to host conference call and webcast on...
Acer Therapeutics Announces Common Stock Purchase Agreement for up to $15 million with Lincoln Park Capital
30 avr. 2020 16h01 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
18 mars 2020 16h05 HE
|
Acer Therapeutics Inc.
OND denies Acer’s appeal but describes possible paths forward for EDSIVO™ ACER-001 bioequivalence trial complete; New Drug Application submission anticipated early 2021 Targeting osanetant Phase...
Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA’s Office of New Drugs
18 mars 2020 16h05 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL®
24 févr. 2020 16h05 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for...
Acer Therapeutics Announces Full Enrollment of Part B in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders
16 déc. 2019 16h05 HE
|
Acer Therapeutics Inc.
Part A Successfully Completed and Optimal Formulation of ACER-001 Identified Results of Part B Expected in Q1 2020 with a Planned NDA Submission in Q1 2021 NEWTON, Mass., Dec. 16, 2019 (GLOBE...
Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
13 nov. 2019 16h05 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...